
Episode 31: Polaris Partners' Amy Schulman
12/29/2025 | 1h 2 mins.
She describes her career beginnings as a lawyer, which led to general counsel and business unit head roles at Pfizer, and then joining the VC world at Polaris Partners (at Bob Langer's urging). She discusses the firm's investment philosophy, the nuances behind how companies choose lead assets, and the cycles biotech has been through over the last ten years. Plus, other roles she currently serves, including being the chair of Alnylam.

Episode 30: F-Prime Capital Senior Managing Partner Stephen Knight
12/15/2025 | 1h
He describes his early life and career experiences at Bell Labs, consulting work, and EPIX Pharmaceuticals before landing in his true interest, venture capital. Dr. Knight describes the foresight of Fidelity to focus on life sciences in its early days, and F-Prime's investing philosophy today.

Episode 29: Averin Managing Partner David Berry
12/01/2025 | 1h 19 mins.
He describes his early life and education, 18 years of company building at Flagship Pioneering, founding Averin (previously called Bedford Bridge) with his brother, and investing at the intersection of healthcare and technology.

Episode 28: Hatteras Venture Partners' Clay Thorp
11/10/2025 | 1h
Clay Thorp describes his early education and becoming a business partner to his brother on a genomics startup. He describes the genesis of Hatteras, the history and strengths of the life sciences ecosystem in the North Carolina area, and his philosophy of backing founders.

Episode 27: Avalon Bioventures' Jay Lichter
10/20/2025 | 1h 3 mins.
Jay Lichter describes his roots growing up in Chicago, Yale, and an early career role at DuPont Merck before getting a call from Kevin Kinsella to try the world of venture at Avalon. Since that pivotal move, he describes numerous companies he either operated or funded, leading to his work today at Avalon Bioventures.



BioVenture VoiCes with Chris Garabedian